AbbVie's stock and next megablockbuster take hits following new JAK warnings from FDA

While the FDA’s new warnings on JAK inhibitors are based on a review of a Pfizer trial, it’s AbbVie that may be hurt the most.

AbbVie’s stock fell by about 10% at one point Wednesday as its prized JAK inhibitor Rinvoq, once forecast to haul in $8 billion annually by 2025, was looped into new class-wide FDA warnings, which include risks of serious heart-related events, cancer, blood clots and death.